Shmuel Ben Zvi
Director/Board Member presso BANK LEUMI LE-ISRAEL B.M.
Patrimonio netto: - $ in data 29/02/2024
Profilo
Shmuel Ben Zvi is on the board of Bank Leumi Le-Israel B.M.
and Protalix Biotherapeutics, Inc. and Manager & Owner at Shmuel (Muli) Ben Zvi Ltd.
He previously occupied the position of Deputy CEO, VP-Finance & Strategy at Teva Pharmaceutical Industries Ltd.
and Head-Budget Department at Israel Ministry of Defense.
He received a doctorate, a graduate degree and an undergraduate degree from Tel-Aviv University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
29/09/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Posizioni attive di Shmuel Ben Zvi
Società | Posizione | Inizio |
---|---|---|
BANK LEUMI LE-ISRAEL B.M. | Director/Board Member | 29/07/2015 |
PROTALIX BIOTHERAPEUTICS, INC. | Director/Board Member | 30/06/2022 |
Shmuel (Muli) Ben Zvi Ltd. | Corporate Officer/Principal | - |
Precedenti posizioni note di Shmuel Ben Zvi
Società | Posizione | Fine |
---|---|---|
NOTABLE LABS, LTD. | Director/Board Member | 16/10/2023 |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01/12/2014 |
Israel Ministry of Defense | Corporate Officer/Principal | 01/01/2004 |
SOL-GEL TECHNOLOGIES LTD. | Director/Board Member | - |
Formazione di Shmuel Ben Zvi
Tel-Aviv University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
BANK LEUMI LE-ISRAEL B.M. | Finance |
SOL-GEL TECHNOLOGIES LTD. | Health Technology |
PROTALIX BIOTHERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Israel Ministry of Defense | Government |
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Shmuel (Muli) Ben Zvi Ltd. |